UC Irvine
Irvine, CA
David Sultzer, MD
Site PI
Dr. David Geldmacher is a Professor and the Vice Chair for Clinical Affairs in the Department of Neurology at the University of Alabama at Birmingham. He holds the Warren Family Endowed Chair in Neurology. Having been involved in AD treatment trials since 1990, he leads the clinical trials program at the UAB Alzheimer’s Disease Center and UAB Hospital’s interprofessional Brain Aging and Memory Clinic. Dr. Geldmacher graduated from the University of Rochester with his B.A. in Biology and Psychology. He obtained his M.D (with Certificate in Academic Research) from the State University of New York Health Science Center at Syracuse. He undertook his Neurology training at Case Western Reserve University and completed a postdoctoral fellowship in Behavioral Neurology at the University of Florida. He is a Fellow of the American College of Physicians and the American Neurological Association. He has been inducted into the Alpha Omega Alpha Medical Honor Society and the Sigma Xi Scientific Research Honor Society. He has been listed in The Best Doctors in America since 1998.
Seyed Ahmad Sajjadi, MD, PhD
Site Co-PI
Dr. Seyed Sajjadi graduated from Tehran University of Medical Sciences before migrating to the United Kingdom to study at the University of Cambridge. Shortly after, he obtained a PhD in neuroscience studying primary progressive aphasia (PPA) before eventually accepting a faculty position at the department of neurology at the University of California, Irvine. Since arriving at UCI, he has become a co-investigator in the 90+ study, an ongoing study of aging and dementia in people aged 90 and older. He is on the faculty of the MiND institute, which is the parent organized research unit (ORU) that hosts UCI Alzheimer’s disease research center (ADRC). Following his interest in primary progressive aphasia, he has established a cohort of patients suffering from this condition at UCI ADRC. He is also studying the impact of cognitive impairment in the utility of common clinical outcome measures used in clinical trials of ALS drugs. Most recently, his lab has been successful in securing an NIH R01 grant to study hippocampal sclerosis of aging, an important yet less studied cause of dementia in the oldest old.
Shirley Sirivong
Site Liaison
Shirley Sirivong has been involved with the UC Irvine Alzheimer’s Disease Research Center since 1994. She currently serves as a clinical research operations manager at UC Irvine. Like many research participants and families, Shirley has a personal family history of Alzheimer’s disease and dementia and is motivated and deeply committed to reduce barriers to clinical research participation and to help make a difference in the fight against Alzheimer’s disease and other neurodegenerative disorders.